Bill Nichols

Bill Nichols is President of Protagenic Therapeutics. He was appointed to his role in February 2026 and is responsible for leading the integrated strategy for the company. He has more than 25 years of biopharma experience with a strong record of leading successful multi-billion-dollar commercial franchises. Most recently as SVP Commercial at bluebird bio (now Genetix), he led the successful launches of three first-in-class gene therapies — LYFGENIA™, ZYNTEGLO™, and SKYSONA™. Earlier in his career he held leadership roles in psychiatry, neuroscience, virology, and blood disorders at Bristol-Myers Squibb and Dova (now Sobi). Mr. Nichols began his career in neuroscience research at Children's Hospital of Philadelphia after receiving a Bachelor of Science in Biology from Morehouse College and has completed executive education at the Wharton School's Aresty Institute.